

**AMENDMENT NUMBER TWENTY-THREE TO THE OPERATING ENGINEERS
LOCAL 139 HEALTH BENEFIT FUND
SUMMARY PLAN DESCRIPTION/PLAN DOCUMENT, 2015 EDITION**

The Operating Engineers Local 139 Health Benefit Fund has adopted the following changes to the Summary Plan Description/Plan Document, 2015 Edition, effective August 15, 2019.

The section entitled Comprehensive Medical Benefit Exclusions and Limitations, on Pages 45-46, is amended to add paragraph 32, as follows:

32. Expenses (medical and/or prescription drug) related to gene therapy, which typically involves replacing a gene that causes a medical problem with one that does not, adding genes to help the body fight or treat disease, or inactivating genes that cause medical problems, whether those therapies have received approval from the U.S. Food and Drug Administration (FDA) or are considered experimental or investigational. Some examples of gene therapy include Chimeric Antigen Receptor T-Cell (CAR-T) Therapies such as Kymriah and Yescarta, as well as other therapies, such as Luxturna and Zolgensma.


The amendment is intended to clarify the Operating Engineers Local 139 Health Benefit Fund Trustees' historical interpretation of the Summary Plan Description/Plan Document, 2015 Edition, and all prior editions, to exclude all gene therapy. This Amendment Number Twenty-Three to the Operating Engineers Local 139 Health Benefit Fund Summary Plan Description/Plan Document, 2015 Edition, was adopted by the Board of Trustees on August 15, 2019.

Union Trustee



Dated: 8-15-2019

Employer Trustee



Dated: 8-15-2019